Literature DB >> 28820070

MUC1 Story: Great Expectations, Disappointments and the Renaissance.

Marina S Syrkina1,2,3, Yegor S Vassetzky2,4,5,6, Mikhail A Rubtsov1,2,3,7.   

Abstract

In the course of studying human mucin MUC1, the attitude towards this molecule has been changing time and again. Initially, the list of presumable functions of MUC1 was restricted to protecting and lubricating epithelium. To date, it is assumed to play an important role in cell signaling as well as in all stages of oncogenesis, from malignant cell transformation to tumor dissemination. The story of MUC1 is full of hopes and disappointments. However, the scientific interest to MUC1 has never waned, and the more profoundly it has been investigated, the clearer its hidden potential turned to be disclosed. The therapeutic potential of mucin MUC1 has already been noted by various scientific groups at the early stages of research. Over forty years ago, the first insights into MUC1 functions became a strong ground for considering this molecule as potential target for anticancer therapy. Therefore, this direction of research has always been of particular interest and practical importance. More than 200 papers on MUC1 were published in 2016; the majority of them are dedicated to MUC1-related anticancer diagnostics and therapeutics. Here we review the history of MUC1 studies from the very first attempts to reveal its functions to the ongoing renaissance. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  MUC1; PEM; anticancer therapy; breast cancer; metastasis; mucin glycoprotein.

Mesh:

Substances:

Year:  2019        PMID: 28820070     DOI: 10.2174/0929867324666170817151954

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  4 in total

1.  YBX1 Enhances Metastasis and Stemness by Transcriptionally Regulating MUC1 in Lung Adenocarcinoma.

Authors:  Qiang Xie; Shilei Zhao; Wenzhi Liu; Yanwei Cui; Fengzhou Li; Zhuoshi Li; Tao Guo; Wendan Yu; Wei Guo; Wuguo Deng; Chundong Gu
Journal:  Front Oncol       Date:  2021-12-15       Impact factor: 6.244

2.  Development of a human antibody fragment directed against the alpha folate receptor as a promising molecule for targeted application.

Authors:  Nattihda Parakasikron; Chatchai Chaotham; Pithi Chanvorachote; Chanida Vinayanuwattikun; Visarut Buranasudja; Pornchanok Taweecheep; Kannika Khantasup
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

3.  Expression of Tumour-Associated MUC1 Is a Poor Prognostic Marker in Breast Cancer in Kumasi, Ghana.

Authors:  E Atta Manu; K Bedu-Addo; N A Titiloye; C Ameh-Mensah; F Opoku; B M Duduyemi
Journal:  J Oncol       Date:  2020-04-22       Impact factor: 4.375

4.  Recombinant nanobody against MUC1 tandem repeats inhibits growth, invasion, metastasis, and vascularization of spontaneous mouse mammary tumors.

Authors:  Parnaz Merikhian; Behrad Darvishi; Neda Jalili; Mohammad Reza Esmailinejad; Azadeh Sharif Khatibi; Shima Moradi Kalbolandi; Malihe Salehi; Marjan Mosayebzadeh; Mahdieh Shokrollahi Barough; Keivan Majidzadeh-A; Fatemeh Yadegari; Fatemeh Rahbarizadeh; Leila Farahmand
Journal:  Mol Oncol       Date:  2021-11-19       Impact factor: 6.603

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.